Neuroptix Closes First Tranche Of Series C Funding At About $4 Million
Neuroptix Corp. closed the first tranche of its Series C funding round at about $4 million. The company plans to use the capital to continue clinical development of its diagnostic platform. The Acton, Mass.-based company that is developing a way to detect Alzheimer’s Disease early through a non-invasive eye test. Inventages Venture Capital GmbH of Switzerland led the investment, which will be funded in two tranches totaling about $8 million, is milestones are successful completed.
10 January 2011•2 mins read
